Focus on Alternative and Complementary Therapies
www.pharmpress.com/fact
Focus Alternat Complement Ther©2005 Pharmaceutical Press
Focus Altern Complement Ther 2006; 11: 24–5
The aim of this study was to investigate the efficacy of a standardised herbal recipe of Chinese herbal medicine (CHM) in the treatment of moderate active Crohn’s disease (CD).
Forty-five patients with mild to moderately active CD were treated in a single university centre for CM and randomly assigned to receive either an encapsuled standardised CHM formula (TCM group, n = 22) or placebo (control group, n = 23). Patients were treated for 12 weeks and followed up for 12 weeks.
No significant changes were observed for CDAI, IBDQ, general well-being, physicians’ and patients’ rating and serummarkers for inflammatory reaction (α1-acid glycoprotein, CRP) at the end of treatment and in the follow-up-assessment.
The chosen standardised CHM formula showed no benefit in the additional treatment of moderately active CD.
This study was supported by a grant from the Rut and Klaus Bahlsen Foundation, Hannover, Germany and the ELAN-Fonds from the University of Erlangen-Nuremberg, Germany. Preparation of trial medication was supported by Raps Co., Spicetrader, Kulmbach, Germany and Wiewelhove GmbH & Co KG, Pharmaceutical Production, Ibbenbüren, Germany.
